Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

5F-AMB

Synthetic cannabinoid of smoking mixtures, full CB1 agonist, three documented deaths.

Narcotic: named in schedule
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₉H₂₆FN₃O₃

CAS 1801552-03-3

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
363.43 g/mol

Updated on

In plain terms

5F-AMB is a molecule made in the laboratory, with no link to the hemp plant. Most often it is smoked after being sprayed on plant material, or vaped as a liquid. It acts on the same receptors as THC. Three deaths with analytical confirmation of the substance have been reported, two of them with other substances present.

Receptors and activity

Target network

CB1AgonistKi = 8.3 nM · human[3H]CP55,940 displacement, human CB1
  • Activates

The lower the cited value, the closer the target sits to 5F-AMB: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 5F-AMB.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1AgonistKi = 8.3 nM · human68 out of 100

    Gamage et al. 2019, J Pharmacol Exp Ther (value reported by WHO, 42nd ECDD, 2019) (new tab) · [3H]CP55,940 displacement, human CB1

  2. CB2AgonistKi = 7.9 nM · human68 out of 100

    Gamage et al. 2019, J Pharmacol Exp Ther (value reported by WHO, 42nd ECDD, 2019) (new tab) · [3H]CP55,940 displacement, human CB2

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

5F-AMB, also called 5F-AMB-PINACA or 5F-MMB-PINACA, is a full agonist at CB1 and CB2 receptors, whereas THC is only a partial agonist. The values gathered in the WHO report (2019) give an affinity of 8.29 nM at human CB1 and 7.93 nM at CB2, with functional EC50 values of 1.3 nM and 0.272 nM ([35S]GTPγS, Gamage et al. 2019). In rodents, the molecule causes hypothermia, locomotor suppression and bradycardia at 0.1-3 mg/kg, effects reversed by a CB1 antagonist, and shifts the balance of excitation and inhibition towards inhibition in layer 5 neurons of the medial prefrontal cortex (Banister et al. 2016; Domoto et al. 2018). The major metabolite, the carboxylic acid produced by hydrolysis of the ester, remains active at both receptors and may prolong the effect (Gamage et al. 2019). Human data, however, are lacking: the active dose is not known and preclinical toxicological evaluation has not been undertaken; one study reports convulsions in 2 of 5 rats after 2.5 mg/kg intraperitoneally. No therapeutic use has been identified.

Key sources.

History

Source
A laboratory molecule with no plant origin. It was identified in 2014 in products sold on the internet in Japan. According to the WHO report (2019), synthetic cannabinoids are mostly synthesised in chemical companies in China, and direct purchase over the internet is common.

Origin

Laboratory synthesis

No biological pathway: 5F-AMB is entirely synthetic and does not occur in hemp. Its structure combines an indazole-3-carboxamide core bearing a 5-fluoropentyl chain on nitrogen 1, linked to a methyl ester of L-valine.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indazole-3-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

5F-AMB (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. WHO, Expert Committee on Drug Dependence, 42nd meeting: critical review report on 5F-AMB (2019) (new tab)
  2. Banister et al. · ACS Chem Neurosci 2016 (new tab)PMID 27421060
  3. Gamage et al. · J Pharmacol Exp Ther 2019 (new tab)PMID 30552295
  4. Andersson et al. · Rapid Commun Mass Spectrom 2016 (new tab)PMID 27003044
  5. Domoto et al. · Psychopharmacology 2018 (new tab)PMID 29858613
  6. Kaneko · Forensic Toxicol 2017 (new tab)PMID 28706566
  7. UNODC, entry into force of the decisions of the 63rd session of the CND (3 November 2020) (new tab)

Identifiers

Names

IUPAC name
methyl (2S)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-3-methylbutanoate
Other names
5F-AMB-PINACA · 5F-MMB-PINACA · 5-Fluoro-AMB

Identifiers

Formula
C₁₉H₂₆FN₃O₃
CAS
1801552-03-3
PubChem CID
119025812(new tab)
InChIKey
SAFXSUZMRLTBMM-INIZCTEOSA-N
SMILES
CC(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CCCCCF

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.